grant

Visual hallucinations and memory impairment in Parkinson's Disease: The role of hippocampal networks

Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 1 Sept 2021Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025Active Follow-upAffectAmentiaAmmon HornAnimalsAnxietyBradykinesiaBrain imagingBrain regionBurden on their caregiversCaregiver BurdenCausalityCharacteristicsClinicalClinical assessmentsCognitiveCognitive DisturbanceCognitive ImpairmentCognitive ManifestationsCognitive SymptomsCognitive declineCognitive function abnormalCornu AmmonisDataDementiaDentate FasciaDevelopmentDiagnosisDisturbance in cognitionDysfunctionEpisodic memoryEtiologyExecutive DysfunctionExecutive Function DeficitExecutive ImpairmentFascia DentataFunctional MRIFunctional Magnetic Resonance ImagingFunctional disorderFunctional impairmentFutureGoalsGyrus DentatusHallucinationsHigh PrevalenceHippocampusHumanHyperactivityImpaired cognitionImpairmentIndividualInterventionLinkMeasuresMemoryMemory DeficitMemory impairmentMental DepressionMethodsModern ManNerve DegenerationNeurobehavioral ManifestationsNeurobehavioral Signs and SymptomsNeuron DegenerationNeuropsychologiesNeuropsychologyNursing HomesParalysis AgitansParkinsonParkinson DiseaseParticipantPatientsPhysiopathologyPlayPredictive ValuePrimary ParkinsonismProcessPsychosesPsychotic DisordersQOLQuality of lifeReportingResolutionRestRiskRoleStructureSymptomsTaxesTemporal LobeTestingTremorVisual HallucinationWorkactive followupbehavior testbehavioral testbrain visualizationburden in caregiversburden of their caregiversburden on caregiverscausationcognitive assessmentcognitive decline in Parkinson'scognitive dysfunctioncognitive dysfunction in Parkinson'scognitive impairment in Parkinson'scognitive losscognitive taskcognitive testingcommon symptomcompare to controlcomparison controldaily functioningdecline in functiondecline in functional statusdementia riskdentate gyrusdepressiondesigndesigningdevelopmentaldisabilitydisease causationepisodic memory impairmentepisodic memory lossexperiencefMRIfollow upfollow-upfollowed upfollowupfunctional declinefunctional status declinehippocampalhippocampal subregionsimage-based methodimaging methodimaging modalityinsightisolated memory lossmedial temporal areamedial temporal lobememory dysfunctionmemory recallmesial temporal areamesial temporal lobemortalitymotor symptomnetwork dysfunctionneural degenerationneural imagingneuro-imagingneurobehavioral symptomneurodegenerationneurodegenerativeneuroimagingneurological degenerationneurological imagingneuronal degenerationneuropsychiatric symptomneuropsychologicnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnon-motor symptomnonmotor symptomnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachnursing homepathophysiologypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypesprognostic abilityprognostic powerprognostic utilityprognostic valuepsychiatric symptompsychotic illnessresolutionsrisk factor for dementiarisk for dementiasocial roletemporal cortexvisual memory
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
Parkinson's disease (PD) is diagnosed based on its characteristic motor symptoms of bradykinesia,

rigidity, and tremor. Increasingly, neuropsychiatric symptoms are identified as part of the neurodegenerative

process of PD. Cognitive impairment and psychosis increase as PD advances and are associated with increased

caregiver burden, impaired daily functioning and nursing home placement, dementia, and greater mortality.

Specifically, memory impairment and hallucinations occur in a subset of PD patients and are associated with an

increased risk for dementia and functional impairment. It is well established that the hippocampus is critically

important for memory function and hippocampal dysfunction has been shown to significantly contribute to

memory impairment in numerous human and animal studies. Similarly, it is now recognized that the hippocampus

plays an important role in the etiology of hallucinations across various psychotic disorders. However, the role of

hippocampal networks in the parallel clinical course of memory impairment and hallucinations in PD remains

unclear. The goal of this project is to assess whether hippocampal network dysfunction provides a shared

mechanism for memory impairment and hallucinations in PD and determine whether increased activity in specific

hippocampal subregions predicts greater cognitive and functional decline longitudinally.

The current project aims to achieve these goals using detailed neuropsychological assessment and high-

resolution functional magnetic resonance imaging (fMRI) methods in PD patients with episodic memory

impairment, PD patients with hallucinations, PD patients without episodic memory impairment or hallucinations,

and healthy controls. A targeted fMRI activation task will be employed designed to tax hippocampal subregion

specific functioning. High-resolution resting-state fMRI will be used to assess connectivity changes between

hippocampal and cortical networks. Clinical and cognitive assessments will be repeated at a two-year follow up

to assess longitudinal change and predictive value of these fMRI markers in the progression of cognitive and

functional decline in PD.

Together the proposed studies will provide insight into the role of the hippocampal network in memory

impairment and hallucinations in PD. The results will determine whether dysfunction in hippocampal subregions

is a marker of episodic memory impairment and hallucinations in PD patients and a predictor of increased risk

for future decline in this subset of patients. Finally, if successful, this work would additionally provide a target for

the development of new therapeutic interventions for memory impairment and hallucinations in PD.

Grant Number: 5R01MH123552-05
NIH Institute/Center: NIH

Principal Investigator: Arnold Bakker

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →